SYVN1 (Gene)

Organism:

Homo sapiens

Synonyms:DER3, ENTREZ:84447, HGNC:20738, HRD1, MIM:608046, NM_032431, NM_172230, NP_115807, NP_757385, SYVN1, XM_011545303, XP_011543605, synoviolin 1

Id:ENSG00000162298

Entrez:84447

Ensembl:ENSG00000162298

Description:synoviolin 1

This gene encodes a protein involved in endoplasmic reticulum (ER)-associated degradation. The encoded protein removes unfolded proteins, accumulated during ER stress, by retrograde transport to the cytosol from the ER. This protein also uses the ubiquitin-proteasome system for additional degradation of unfolded proteins. Sequence analysis identified two transcript variants that encode different isoforms. [provided by RefSeq, May 2011]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SYVN1's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SYVN1.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SYVN1.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SYVN1.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SYVN1.

Results found

Linked to

	Label	Description
	GSE242555 1 V 0 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 3 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE163862 2 V 3 CISPLATIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 12 V 6 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE57871 GLI1 PSMD13 knockdown HCT 116 Vorinostat 11 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE57871 vorinostat HCT 116 11 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE242555 1 V 0 NICOTINAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 3 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE163862 2 V 3 CISPLATIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 12 V 6 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 8 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE57871 GLI1 PSMD13 knockdown HCT 116 Vorinostat 11 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE57871 vorinostat HCT 116 11 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.